When did IMMUNOPRECISE ANTIBODIES LTD (IPA) report earnings last quarter?
IMMUNOPRECISE ANTIBODIES LTD (IPA) last reported earnings on 9/11/2025.
IMMUNOPRECISE ANTIBODIES LTD (IPA) Earnings History & Surprises
NASDAQ:IPA • CA45257F2008
Current stock price
2.07 USD
+0.14 (+7.25%)
At close:
2.12 USD
+0.05 (+2.42%)
After Hours:
IPA Earnings overview
Past quarterly earnings results for IMMUNOPRECISE ANTIBODIES LTD (IPA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Dec 8, 2025
- Period
- Q1 / 2026
- EPS Estimate
- -CA$0.06
- Revenue Estimate
- 6.313M
Last Reported
Most Recent- Release Date
- Sep 11, 2025
- Period
- Q4 / 2025
- EPS Reported
- -CA$0.05
- EPS Surprise
- 0.99%
- Revenue Surprise
- -12.40%
Beat Rate
Last 8 Quarters 56%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in CAD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.05 | -0.05 | 0.99% | 54.55% | 6.981M | 7.969M | -12.40% | 8.08% |
| Q3 2025 | -0.01 | -0.08 | 87.62% | 90.91% | 6.151M | 6.651M | -7.52% | -1.13% |
| Q2 2025 | -0.09 | -0.10 | 6.20% | 10.00% | 6.125M | 6.503M | -5.81% | -0.41% |
| Q1 2025 | -0.15 | -0.11 | -35.01% | -7.14% | 5.263M | 6.818M | -22.81% | -7.47% |
| Q4 2024 | -0.11 | -0.12 | 5.29% | 47.62% | 6.459M | 6.595M | -2.06% | 15.34% |
| Q3 2024 | -0.11 | -0.10 | -8.91% | 42.11% | 6.221M | 6.129M | 1.50% | 20.31% |
| Q2 2024 | -0.10 | -0.13 | 23.84% | 66.67% | 6.15M | 5.911M | 4.04% | 18.63% |
| Q1 2024 | -0.14 | -0.21 | 32.38% | 64.60% | 5.688M | 5.404M | 5.26% | 21.31% |
| Q4 2023 | -0.21 | -0.17 | -22.31% | -196.53% | 5.6M | 5.763M | -2.83% | 6.89% |
| Q3 2023 | -0.19 | -0.23 | 18.21% | 5.00% | 5.171M | 5.488M | -5.78% | 7.39% |
| Q2 2023 | -0.30 | -0.19 | -56.33% | -15.38% | 5.184M | 5.315M | -2.46% | 9.78% |
| Q1 2023 | -0.40 | - | - | 4.689M | - | 2.20% | ||
| Q4 2022 | 0.22 | - | 226.70% | 5.239M | - | 7.43% | ||
| Q3 2022 | -0.20 | -0.16 | -23.76% | -150.00% | 4.815M | 5.353M | -10.05% | 6.62% |
| Q2 2022 | -0.26 | -0.17 | -51.43% | -766.67% | 4.722M | 5.05M | -6.50% | -0.69% |
| Q1 2022 | - | - | 4.588M | - | 21.86% | |||
| Q4 2021 | -0.17 | - | -243.40% | 4.877M | 5.05M | -3.44% | 17.65% | |
| Q3 2021 | -0.08 | -0.18 | 54.31% | -166.67% | 4.516M | 6.114M | -26.14% | 11.94% |
| Q2 2021 | -0.03 | -0.15 | 80.58% | 70.00% | 4.755M | 6.09M | -21.93% | 50.35% |
| Q1 2021 | -0.10 | -0.14 | 30.65% | -100.00% | 3.765M | 5.974M | -36.98% | 38.62% |
| Q4 2020 | -0.05 | -0.02 | -142.72% | - | 4.145M | 4.886M | -15.17% | - |
| Q3 2020 | -0.03 | 0.00 | - | - | 4.034M | 4.616M | -12.61% | - |
| Q2 2020 | -0.10 | 0.00 | - | - | 3.162M | 4.216M | -24.99% | - |
| Q1 2020 | -0.05 | - | - | 2.716M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
14.95%
Max EPS beat (4)
87.62%
Min EPS beat (4)
-35.01%
Revenue beat statistics
Revenue beat (4)
0
Average Revenue beat (4)
-12.13%
Max Revenue beat (4)
-5.81%
Min Revenue beat (4)
-22.81%
Analysis
In the last 4 quarters, IPA has beaten EPS estimates in 3 out of 4 releases
IPA has not beaten revenue estimates in any of the last 4 earnings releases
In the last 4 quarters, IPA has beaten the EPS estimates by 15.0% on average.
In the last 4 quarters, IPA reported -12.1% below the revenue estimates on average.
Related analysis
IMMUNOPRECISE ANTIBODIES LTD / IPA Earnings FAQ
Did IPA stock beat earnings estimates in the most recent quarter?
IMMUNOPRECISE ANTIBODIES LTD (IPA) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often IMMUNOPRECISE ANTIBODIES LTD beats earnings estimates?
In the last 4 quarters, IMMUNOPRECISE ANTIBODIES LTD (IPA) has beaten EPS estimates in 3 out of 4 releases.